Surrozen, Inc./De (SRZNW) — SEC Filings
Surrozen, Inc./De (SRZNW) — 33 SEC filings. Latest: 10-Q (Nov 7, 2025). Includes 13 8-K, 5 10-Q, 5 SC 13G.
View Surrozen, Inc./De on SEC EDGAR
Overview
Surrozen, Inc./De (SRZNW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 7, 2025: Surrozen, Inc. (SRZNW) reported a significant increase in net loss for the three months ended September 30, 2025, reaching $71.6 million, a substantial rise from $1.4 million in the same period of 2024. The nine-month net loss also widened to $58.9 million in 2025 from $35.5 million in 2024. Total r
Sentiment Summary
Across 33 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 30 neutral. The dominant filing sentiment for Surrozen, Inc./De is neutral.
Filing Type Overview
Surrozen, Inc./De (SRZNW) has filed 5 10-Q, 13 8-K, 2 DEF 14A, 2 10-K, 4 SC 13G/A, 5 SC 13G, 2 SC 13D/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (33)
Risk Profile
Risk Assessment: Of SRZNW's 21 recent filings, 2 were flagged as high-risk, 12 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $983K |
| Net Income | -$71.6M |
| EPS | -$8.36 |
| Debt-to-Equity | N/A |
| Cash Position | $81.3M |
| Operating Margin | -1106.7% |
| Total Assets | $94.0M |
| Total Debt | $117.6M |
Key Executives
- Dr. Jonathan Leff
- Dr. David Sidransky
- Craig Parker
- TIM KUTZKEY
- James Evangelista
- Tim Kutzkey
Industry Context
Surrozen operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel therapeutics. The industry is characterized by long development cycles, significant R&D investment, and high failure rates. Success often hinges on scientific innovation, successful clinical trials, and securing substantial funding to navigate the path to market.
Top Tags
warrants (4) · Biotechnology (3) · material-agreement (3) · financials (3) · 10-Q (3) · biotech (3) · Surrozen (3) · amendment (3) · material-definitive-agreement (2) · Warrants (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $71.6M | Increased from $1.4M in Q3 2024 |
| Net Loss (9 months 2025) | $58.9M | Increased from $35.5M in 9 months 2024 |
| Total Revenue (Q3 2025) | $983K | Decreased from $10.0M in Q3 2024 |
| Research and Development Expenses (Q3 2025) | $7.8M | Increased from $5.2M in Q3 2024 |
| Loss on execution of 2025 PIPE | $71.1M | Significant non-operating expense |
| Cash and Cash Equivalents (Sept 30, 2025) | $81.3M | Increased from $34.6M at Dec 31, 2024 |
| Accumulated Deficit (Sept 30, 2025) | $344.1M | Indicates significant historical losses |
| Proceeds from 2025 PIPE | $71.2M | Primary source of cash increase |
| Net loss per share (Q3 2025) | $8.36 | Increased from $0.44 in Q3 2024 |
| SEC File Number | 001-39635 | Identifies Surrozen's filing with the SEC |
| IRS Employer Identification No. | 30-1374889 | Tax identification for Surrozen |
| Revenue | $0 | for the three and six months ended June 30, 2025, indicating pre-commercialization stage |
| Date of Series D Common Stock Private Placement | 2024-04-30 | indicates a key capital raise event |
| Start Date of Series A Common Stock Private Placement | 2025-01-01 | indicates ongoing capital raising activities |
| End of Reporting Period | 2025-06-30 | financial data up to this date |
Forward-Looking Statements
- {"claim":"Surrozen, Inc./DE's stock price may experience increased investor interest due to Goldman Sachs's significant stake.","entity":"Surrozen, Inc./DE","targetDate":"Q1 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Surrozen, Inc./De (SRZNW)?
Surrozen, Inc./De has 33 recent SEC filings from Jan 2024 to Nov 2025, including 13 8-K, 5 10-Q, 5 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SRZNW filings?
Across 33 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 30 neutral. The dominant sentiment is neutral.
Where can I find Surrozen, Inc./De SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Surrozen, Inc./De (SRZNW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Surrozen, Inc./De?
Key financial highlights from Surrozen, Inc./De's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SRZNW?
The investment thesis for SRZNW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Surrozen, Inc./De?
Key executives identified across Surrozen, Inc./De's filings include Dr. Jonathan Leff, Dr. David Sidransky, Craig Parker, TIM KUTZKEY, James Evangelista and 1 others.
What are the main risk factors for Surrozen, Inc./De stock?
Of SRZNW's 21 assessed filings, 2 were flagged high-risk, 12 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Surrozen, Inc./De?
Recent forward-looking statements from Surrozen, Inc./De include guidance on {"claim":"Surrozen, Inc./DE's stock price may experience increased investor interest due to Goldman Sachs's significant .